IRIS Accounts Production v24.3.2.46 13417780 director 1.6.23 31.5.24 31.5.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh134177802023-05-31134177802024-05-31134177802023-06-012024-05-31134177802022-05-31134177802022-06-012023-05-31134177802023-05-3113417780ns15:EnglandWales2023-06-012024-05-3113417780ns14:PoundSterling2023-06-012024-05-3113417780ns10:Director12023-06-012024-05-3113417780ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3113417780ns10:SmallEntities2023-06-012024-05-3113417780ns10:AuditExempt-NoAccountantsReport2023-06-012024-05-3113417780ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3113417780ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3113417780ns10:FullAccounts2023-06-012024-05-3113417780ns10:OrdinaryShareClass12023-06-012024-05-3113417780ns5:CurrentFinancialInstruments2024-05-3113417780ns5:CurrentFinancialInstruments2023-05-3113417780ns5:ShareCapital2024-05-3113417780ns5:ShareCapital2023-05-3113417780ns5:RetainedEarningsAccumulatedLosses2024-05-3113417780ns5:RetainedEarningsAccumulatedLosses2023-05-3113417780ns10:RegisteredOffice2023-06-012024-05-3113417780ns5:ComputerEquipment2023-06-012024-05-3113417780ns5:ComputerEquipment2023-05-3113417780ns5:ComputerEquipment2024-05-3113417780ns5:ComputerEquipment2023-05-3113417780ns5:WithinOneYearns5:CurrentFinancialInstruments2024-05-3113417780ns5:WithinOneYearns5:CurrentFinancialInstruments2023-05-3113417780ns5:AcceleratedTaxDepreciationDeferredTax2024-05-3113417780ns5:AcceleratedTaxDepreciationDeferredTax2023-05-3113417780ns5:DeferredTaxation2023-05-3113417780ns5:DeferredTaxation2023-06-012024-05-3113417780ns5:DeferredTaxation2024-05-3113417780ns10:OrdinaryShareClass12024-05-31134177801ns10:Director12023-05-31134177801ns10:Director12022-05-31134177801ns10:Director12023-06-012024-05-31134177801ns10:Director12022-06-012023-05-31134177801ns10:Director12024-05-31134177801ns10:Director12023-05-31
REGISTERED NUMBER: 13417780 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED

31 MAY 2024

FOR

SLATER DERMATOLOGY LTD

SLATER DERMATOLOGY LTD (REGISTERED NUMBER: 13417780)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024










Page

Balance Sheet 1

Notes to the Financial Statements 3


SLATER DERMATOLOGY LTD (REGISTERED NUMBER: 13417780)

BALANCE SHEET
31 MAY 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 5 2,940 448

CURRENT ASSETS
Debtors 6 47,762 9,981
Cash at bank 49,701 16,479
97,463 26,460
CREDITORS
Amounts falling due within one year 7 99,356 26,795
NET CURRENT LIABILITIES (1,893 ) (335 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,047

113

PROVISIONS FOR LIABILITIES 8 735 112
NET ASSETS 312 1

CAPITAL AND RESERVES
Called up share capital 9 1 1
Retained earnings 311 -
SHAREHOLDERS' FUNDS 312 1

SLATER DERMATOLOGY LTD (REGISTERED NUMBER: 13417780)

BALANCE SHEET - continued
31 MAY 2024


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 19 February 2025 and were signed by:





Dr J C Slater - Director


SLATER DERMATOLOGY LTD (REGISTERED NUMBER: 13417780)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024


1. STATUTORY INFORMATION

Slater Dermatology Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 13417780

Registered office: 48 St Leonards Road
Bexhill on Sea
East Sussex
TN40 1JB

The presentation currency of the financial statements is the Pound Sterling (£).


2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Turnover
The turnover shown in the profit and loss account represents amounts receivable for
services provided during the period.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Equipment - straight line over 3 years

SLATER DERMATOLOGY LTD (REGISTERED NUMBER: 13417780)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


3. ACCOUNTING POLICIES - continued

Financial instruments
The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities, like trade and other accounts receivable and payable, loans from banks and other third parties and loans to / from related parties.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at the present value of the future cash flows and subsequently measured at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted transaction price less any impairment.

If the arrangements of a short term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate, the
Financial liabilities and equity instruments are classified according to the substance of the
contractual arrangements entered into. An equity instrument is any contract that evidences a
residual interest in the assets of the entity after deducting all of its financial liabilities.

Where the contractual obligations of financial instruments (including share capital) are
equivalent to a similar debt instrument, those financial instruments are classed as financial
liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and
gains or losses relating to financial liabilities are included in the profit and loss account.
Finance costs are calculated so as to produce a constant rate of return on the outstanding
liability.

Where the contractual terms of share capital do not have any terms meeting the definition of
a financial liability then this is classed as an equity instrument. Dividends and distributions
relating to equity instruments are debited direct to equity.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


SLATER DERMATOLOGY LTD (REGISTERED NUMBER: 13417780)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


3. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 1 ) .

5. TANGIBLE FIXED ASSETS
Equipment
£   
COST
At 1 June 2023 598
Additions 3,521
At 31 May 2024 4,119
DEPRECIATION
At 1 June 2023 150
Charge for year 1,029
At 31 May 2024 1,179
NET BOOK VALUE
At 31 May 2024 2,940
At 31 May 2023 448

SLATER DERMATOLOGY LTD (REGISTERED NUMBER: 13417780)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Other debtors 1,863 -
Directors' current accounts 45,074 9,981
Prepayments and accrued income 825 -
47,762 9,981

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Corporation tax 95,891 25,333
PAYE and social security 1,417 -
Other creditors 211 -
Accruals and deferred income 1,837 1,462
99,356 26,795

8. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax
Accelerated capital allowances 735 112

Deferred
tax
£   
Balance at 1 June 2023 112
Provided during year 623
Balance at 31 May 2024 735

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
1 Ordinary £1 1 1

SLATER DERMATOLOGY LTD (REGISTERED NUMBER: 13417780)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024


10. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 May 2024 and 31 May 2023:

2024 2023
£    £   
Dr J C Slater
Balance outstanding at start of year - -
Amounts advanced 45,075 -
Amounts repaid - -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 45,075 -

Interest was charged at 2.25% per annum on advances to the director exceeding £10,000. The interest charged in the year amounted to £146 (2023: £Nil).